EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · IEX Real-Time Price · USD
16.75
+0.59 (3.65%)
At close: Apr 26, 2024, 4:00 PM
16.33
-0.42 (-2.51%)
After-hours: Apr 26, 2024, 7:46 PM EDT
EyePoint Pharmaceuticals Employees
EyePoint Pharmaceuticals had 121 employees on December 31, 2023. The number of employees decreased by 23 or -15.97% compared to the previous year.
Employees
121
Change (1Y)
-23
Growth (1Y)
-15.97%
Revenue / Employee
$380,314
Profits / Employee
-$585,083
Market Cap
834.67M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 121 | -23 | -15.97% |
Dec 31, 2022 | 144 | 21 | 17.07% |
Dec 31, 2021 | 123 | 22 | 21.78% |
Dec 31, 2020 | 101 | 17 | 20.24% |
Dec 31, 2019 | 84 | 40 | 90.91% |
Dec 31, 2018 | 44 | 22 | 100.00% |
Jun 30, 2017 | 22 | 2 | 10.00% |
Jun 30, 2016 | 20 | -6 | -23.08% |
Jun 30, 2015 | 26 | 2 | 8.33% |
Jun 30, 2014 | 24 | -1 | -4.00% |
Jun 30, 2013 | 25 | -4 | -13.79% |
Jun 30, 2012 | 29 | 3 | 11.54% |
Jun 30, 2011 | 26 | 3 | 13.04% |
Jun 30, 2010 | 23 | 1 | 4.55% |
Jun 30, 2009 | 22 | 1 | 4.76% |
Jun 30, 2008 | 21 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
EYPT News
- 11 days ago - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists - GlobeNewsWire
- 7 weeks ago - EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 7 weeks ago - EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer - GlobeNewsWire
- 2 months ago - EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 - GlobeNewsWire
- 2 months ago - EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration - GlobeNewsWire
- 3 months ago - EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - GlobeNewsWire